GLPwatch
Bioenergetic Alterations After Exenatide Administration
NCT00623545 · Completed
Last updated 2026-05-28This clinical trial tested how the medication exenatide affects energy intake in healthy individuals by comparing measurements before and after treatment.
Status Completed The study has finished.
Phase Phase 4 Monitors a drug already on the market.
Type Interventional (clinical trial)
Design open-label (no blinding) treatment study
Participants 28 people
Who can join Ages 18–65 · all sexes Healthy volunteers accepted.
Timeline Started 2008-01 · est. completion 2010-04
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT00623545 ↗
Description as written by the study sponsor.
The purpose of this study is to find out how exenatide causes weight loss. Specifically, the study is assessing how exenatide may change how people take in energy (energy intake), as well as how it may effect how people use energy (energy expenditure).
Treatments tested
- Exenatide also known as Byetta Drug
Exenatide dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks of treatment.
| Main thing measured | Change in Energy Intake Measured Before Treatment and at the End of Treatment. |
|---|---|
| Sponsor | University of Wisconsin, Madison |
| Conditions studied | Healthy |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00623545 ↗